CS
RCUS icon

Candriam SCA’s Arcus Biosciences RCUS Stock Holding History

Candriam SCA’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4M Sell
661,981
-128,632
-16% -$3.18M 0.09% 199
2026
Q1 		$17.1M Hold
790,613
– – 0.09% 213
2025
Q4 		$18.8M Buy
790,613
+412,172
+109% +$8.41M 0.09% 197
2025
Q3 		$5.15M Buy
+378,441
New +$3.93M 0.03% 365
2021
Q2 		– Sell
-408,991
Closed -$10.2M – 931
2021
Q1 		$10.2M Sell
408,991
-15
-0% -$522 0.08% 248
2020
Q4 		$10.6M Sell
409,006
-79,664
-16% -$1.93M 0.08% 252
2020
Q3 		$8.38M Buy
488,670
+265,728
+119% +$5.94M 0.08% 264
2020
Q2 		$5.51M Buy
+222,942
New +$6.02M 0.06% 313

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Candriam SCA's RCUS Position: Q2 2026 in Review

Candriam SCA reduced its Arcus Biosciences (RCUS) stake by 16% in Q2 2026, selling an estimated $3.18M and leaving 661,981 shares worth $20.4M. The position accounts for 0.09% of the portfolio, ranked #199.

Candriam SCA first reported a position in RCUS in Q2 2020 and has held it in 8 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Candriam SCA held 661,981 shares of Arcus Biosciences worth $20.4M as of Q2 2026.
  • Candriam SCA sold 128,632 Arcus Biosciences shares in Q2 2026, an estimated $3.18M.
  • Arcus Biosciences made up 0.09% of Candriam SCA's portfolio in Q2 2026, its #199 holding.
  • Candriam SCA first reported a position in Arcus Biosciences in Q2 2020 and has held it in 8 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.